ScreenerHero

LRMRLarimar Therapeutics, Inc.

NAS · US · Healthcare · Biotechnology · larimartx.com
4.180USD-1.65%Mkt Cap: 434.23M $P/E: —

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601,…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap434.23M $
Enterprise Value282.92M $
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-165.67M $
Revenue/Share—
Last Price4.180 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees71
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-3.92
PEG—
EV/EBITDA-1.58
EV/Revenue—
P/S—
P/B3.41
EPS (TTM)-1.96
EPS (Forward)-1.06
52W Range
2.71540% of range6.420
52W High6.420 USD
52W Low2.715 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-212.17%
ROA-113.60%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-113.20M $
CapEx (TTM)91.00K $
FCF Margin—
FCF Yield-21.69%
Net Debt-151.31M $
Net Debt/EBITDA0.85
Balance Sheet
Debt/Equity0.05
Current Ratio4.70
Quick Ratio4.58
Book Value/Sh1.220 USD
Cash/Share1.497 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay DateMay 29, 2020
Analyst Consensus
Rating1.2 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)14.30 USD
Upside (mean)+242.1%
Target Range5.000 USD – 26.00 USD
$5.000+242.1% to mean$26.00
# Analysts10
Ownership
Shares Out.103.88M
Float57.90M
Insiders1.15%
Institutions93.39%
Short Interest
Short Ratio6.6d
Short % Float18.13%
Short % Out.11.73%
Shares Short12.19M
Short (prev mo.)12.19M
Technical
SMA 503.805 (+9.8%)
SMA 2003.905 (+7.0%)
Beta0.75
S&P 52W Chg18.16%
Avg Vol (30d)1.44M
Avg Vol (10d)1.17M
Technical Indicators
RSI (14)55.0
MACD0.1421
MACD Signal0.1398
MACD Hist.+0.0023
BB Upper4.503 USD
BB Middle4.078 USD
BB Lower3.654 USD
BB Width20.82%
ATR (14)0.2328 USD
Vol Ratio (20d)0.56x